PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth - - BioPharm International

ADVERTISEMENT

PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth



The Pharmaceutical Research and Manufacturers of America (PhRMA) released a report that outlines two potential growth trajectories for the US biopharmaceutical sector. Developed by the Battelle Technology Partnership Practice, the report finds that coverage and payment policies, a science-based regulatory system, and strong intellectual property (IP) protections drive US leadership in biopharmaceutical innovation, and if negative trends in these key policy areas continue, jobs supported by the industry would decrease over the next decade. However, if reasonable pro-innovation policies are pursued, the biopharmaceutical sector stands to retain and addover 300,000 jobs by 2021. The report combines quantitative data with inputfrom industry leaders.

As the ability to innovate is increasingly becoming the most important determinant of a nation’s future potential for economic growth and global competitiveness, the biopharmaceutical industry stands out among manufacturing industries as an example for future economic growth, the report says. Currently, the biopharmaceutical industry supports a total of 3.4 million jobs across the US economy, including over 810,000 direct jobs, contributes $789billion in economic output, and is responsible for about one in five dollars spent on R&D by US businesses. To put into greater context, biopharmaceutical companies invested more than nine times the amount of R&D per employee than manufacturing industries overall from 2000 to 2010.

Not only have PhRMA member companies invested an estimated $51.1 billion in R&D in 2013, representing the majority of all biopharmaceutical R&D spending in the US, but the medicines developed by the industry play an important role in helping control other health care costs. For example, theCongressional Budget Office recently adopted a scoring change that credits Medicare policies that increase use of medicines with savings on other Medicare costs. Similarly, Harvard researchers report savings on hospital and nursing facility costs of about $1200 per newly insured Part D beneficiary in 2007.This equals overall Medicare savings of $13.4 billion, more than one quarter of Part D’s total cost during the program’s first full year.

Source: Pharmaceutical Research and Manufacturers of America

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
USP Center in Ghana Receives International Lab Accreditation
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Report Predicts Generics Production Return to US
August 15, 2014
Author Guidelines

Click here